Oklahoma's Syringe Law Died on Schedule. Washington Made Sure Nothing Would Replace It.

At 10 a.m. on June 25, in a small office off Highway 64 in Tulsa, Tyler Read sat down to fold syringes into kits one more time. He and the other volunteers at the Oklahoma Harm Reduction Alliance had done this every Thursday for years — 150 to 200 kits a shift, 300 to 400 sterile syringes, packed next to naloxone and wound-care supplies under a wall of photographs of people who didn’t make it. This was the last regular session before the law that let them do this legally expired. On July 1, Oklahoma’s five-year shield for syringe service programs sunset on schedule, and nobody in Oklahoma City stopped it.

Washington made sure that if a state let harm reduction lapse this year, there’d be less federal money left to catch it.

That’s not a coincidence of timing so much as a convergence of two decisions, made roughly 1,500 miles and several months apart, that land on the same people at the same moment. One is a state legislature’s failure to renew a law it always knew would expire. The other is a federal “Dear Colleague” letter, issued April 24 by SAMHSA, that tells every county and nonprofit drawing on federal block grants they can no longer buy fentanyl test strips, xylazine test strips, or medetomidine test strips with that money. Sterile water, saline, and ascorbic acid — the supplies that keep an injection from turning into an abscess — are out too. So are overdose hotlines. Naloxone stays funded. So does wound care and HIV/hepatitis testing. But the tools that tell someone what’s actually in the drug they’re about to use are, as of this spring, off the federal menu.

If you have ever used a test strip before you used, you already know exactly what that dollar buys, and it isn’t nothing.

The clause that was always going to expire, and the review that never happened

Oklahoma’s law, Senate Bill 511, passed in 2021 with a deliberate five-year sunset — a compromise former state Rep. Carol Bush and Sen. John Montgomery struck to get a conservative legislature to protect syringe programs from paraphernalia prosecution at all. The deal, as Bush now describes it, was that lawmakers would revisit the law in five years, look at what had happened to Hepatitis C rates, HIV rates, and needle-stick injuries among police officers, and decide whether to keep it. “I’m not sure that conversation ever happened,” Bush told Oklahoma Watch. It didn’t. A 2025 renewal bill from Rep. Daniel Pae, which originally sought to remove the sunset date entirely, passed the House with only a one-year extension and was never heard in the Senate. It just died there.

In plain terms: block grants are the federal government’s way of handing states and counties a lump of money for behavioral health, instead of funding each program line by line. Whoever controls the conditions attached to that lump sum controls what actually gets built with it — and in 2026, the conditions changed. Between 2022 and Oklahoma’s last full accounting, the state’s programs distributed 1.25 million syringes and reached roughly 8,800 people across 77 counties. The Oklahoma Harm Reduction Alliance alone estimates it prevented around 300 overdoses in that stretch. “That’s 300 families that we got saved together,” Tyler Read said. “We kept them from that tragedy.” Laurel Taylor, the Alliance’s secretary, joined the work after her ex-husband died from drug use; her son Isaac sometimes comes along on kit-packing shifts. “He understands that this is about saving lives,” she said, “having made these overdose reversal kits.”

None of that evidence moved the needle in the Oklahoma Senate. And the reason isn’t only local. Michael Olson of Oklahomans for Criminal Justice Reform pointed to the chilling effect radiating out from Washington: conservative legislators who might have quietly backed a renewal a few years ago now had a presidential executive order on the books instructing federal agencies to fund only programs that “achieve adequate outcomes” and to treat harm reduction itself as something that “only facilitates illegal drug use.” Signing a renewal bill started to look, to some of them, like signing up for a fight they didn’t need before their next primary.

What the federal letter actually kills — and what it protects on paper

It’s worth being precise about what changed at the federal level in April, because the SAMHSA letter is more surgical than the political rhetoric around it suggests. STAT News reported that the guidance draws a line: naloxone and nalmefene, medication lock boxes, overdose-reversal training, and HIV/hepatitis prevention services all remain eligible for Mental Health Block Grant and Substance Use Block Grant dollars. What’s now explicitly barred is the category of supplies that let a person who uses drugs find out what’s actually in the batch before it kills them, plus the basic sterile-injection supplies that keep a habit from turning into a hospitalization.

It’s worth being precise about what changed at the federal level in April, because the SAMHSA letter is more surgical than the political rhetoric around it suggests.

This is the implementation gate that matters for anyone reading this as a provider or a case manager: a federal letter changing what block-grant money can buy is not the same thing as a state banning test strips outright. Thirty-seven states, as of this spring, still allow syringe service programs to operate under state law. What’s disappeared is the money that let many of them run at scale. A county health department that wants to keep handing out xylazine test strips can still do it — it just has to find dollars that didn’t used to have to come from anywhere else, because SAMHSA’s block grant used to cover it. The National Association of Counties was blunt about what that means for the roughly $130 billion counties already spend on community health systems every year: this is a cost shift, dressed up as a values statement, landing on the same local budgets that are also trying to absorb Oklahoma’s expired law. And the same April letter didn’t stop at fentanyl and xylazine — it named medetomidine test strips too, the newest tranquilizer contaminant now spreading through the fentanyl supply, meaning the newest threat got cut out of federal funding on the same page as the oldest harm-reduction tool in the room.

We already ran this experiment, in West Virginia, in 2018

If this feels like a hypothetical, it isn’t. In March 2018, Charleston, West Virginia’s mayor forced the closure of the city’s publicly-run syringe service program over his objections to it. Filter’s reporting from the aftermath documented what happened next in neighboring Cabell County: a region that expected roughly eight new HIV diagnoses a year among all at-risk groups combined instead recorded 17 diagnoses among people who inject drugs in 2018 alone, then seven more in the fourth quarter and thirteen more in the first months of 2019 — the pace accelerating, not slowing, as the closure aged. Access to sterile syringes evaporated fast enough that street vendors started charging up to six dollars apiece. “They’re like gold out here now,” one 29-year-old told Filter. A 35-year-old, describing what happens when you can’t find a clean one, put it flatly: “You want it so bad, you’re like, man, I don’t care. I’ll give you 10 bucks for that needle, just give it to me.”

That’s the historical shape of this exact policy move: a program closes, the drugs don’t stop, and the only thing that changes is whether the person using them can do it without also picking up HIV or Hepatitis C on the way. Oklahoma and the counties absorbing SAMHSA’s new restrictions are running the same experiment now, at a larger scale, with a firmer federal hand pushing from behind.

The number nobody has managed to rebut

The strongest evidence against this whole approach didn’t come from an advocacy group. It came from a modeling study in JAMA Network Open, published June 18 by researchers at the University of Colorado Anschutz and University of Miami. A microsimulation model — in plain terms, a computer model built from real surveillance data that plays out what happens to a simulated population of millions of people who inject drugs, under different funding scenarios — tracked 3.69 million people who inject drugs nationally across five years, from August 2025 to August 2030. Under the mildest scenario the researchers tested — an 11% funding cut lasting just one year — the model still projected 1,100 additional deaths, 500 of them overdose-specific. Under the harshest scenario — an 80% cut sustained for the full five years — the number climbs to 39,600 additional deaths, 15,600 of them overdose-specific.

“Even relatively modest reductions in services will be associated with increased mortality,” said Dr. Kirk Fetters, the study’s co-first author. Every scenario the team modeled, mild or severe, produced excess deaths compared to keeping current funding in place — there was no version of this policy that came back cost-free. That’s the caveat worth stating alongside the headline number, because it’s also the finding: this isn’t a study with a wide error bar around whether cuts cause harm. It’s a study with a wide error bar around how much harm, tested against every scenario the researchers could construct, and every one of them showed more people dying, not fewer. “Policies that reduce access to these services will have far-reaching consequences,” said Dr. Josh Barocas, the senior author.

That’s the caveat worth stating alongside the headline number, because it’s also the finding: this isn’t a study with a wide error bar around whether cuts cause harm.

If you’re a case manager or a facility administrator reading this before your next team meeting, that’s a concrete question worth putting on the agenda this week: does your county’s block-grant funding still cover test strips or sterile injection supplies today, or did it quietly stop in April? Most front-line staff won’t know the answer until someone asks it out loud.

What’s still yours, even now

Here is the part that doesn’t change no matter what a legislature or a federal letter does: naloxone is still federally fundable, in Oklahoma and everywhere else, and it still reverses an opioid overdose whether or not the test strip that might have prevented it existed. The Cherokee Nation’s harm reduction program — which has disposed of 160,000 used syringes and handed out more than 160,000 sterile ones and 20,000 doses of Narcan since 2023 — isn’t shutting down on July 1; Principal Chief Chuck Hoskin Jr. has said plainly the sunset “is going to result in more people sick or dying,” and his program is staying open on tribal land regardless of what happened in the state Senate. HOPE Tulsa, which distributed 419,000 sterile syringes in 2025 alone, plans to keep going within whatever the new legal limits allow. Rep. Pae says he’ll bring a renewal bill back next session. None of that is nothing, and none of it should be mistaken for the thing that just ended.

We have been here before, and the ending wasn’t fixed in advance — it was decided, in Charleston in 2018 and now in Oklahoma City in 2026, by people who could have chosen otherwise. Jeff Burdge of HOPE Tulsa put the stakes as plainly as anyone: “What I think sometimes gets lost in these conversations is that harm reduction is really about keeping people alive and healthy long enough to access treatment and care when they’re ready.” Tyler Read is going to keep folding kits on Thursdays for as long as the law allows him to, and probably a little past that. The question this story actually leaves open isn’t whether harm reduction works. It’s how many more Cabell Counties it takes before that stops being an open question at all.